{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T13:51:10Z","timestamp":1752673870479},"reference-count":0,"publisher":"Oceanside Publications Inc.","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["allergy asthma proc"],"published-print":{"date-parts":[[2020,5,1]]},"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> Oral corticosteroid (OCS) dependent asthma is one of the severe asthma phenotypes that requires personalized treatment.  <jats:bold>Objective:<\/jats:bold> To review the role of biologic treatments in OCS-dependent asthma.  <jats:bold>Methods:<\/jats:bold> A nonsystematic\n review was performed of emerging multiple novel biologics for potential treatment of OCS-dependent asthma.  <jats:bold>Results:<\/jats:bold> The serious adverse effects of OCS can be seen as a result of their regular long-term administration. Anti\u2010interleukin (IL) 5 (mepolizumab), anti\u2010IL-5R\n (benralizumab), and anti\u2010IL-4R\u03b1 (dupilumab) are the therapies of choice for OCS-dependent severe asthma. Results of studies showed the efficacy of mepolizumab, benralizumab, and dupilumab, especially in patients with the OCS-dependent severe eosinophilic asthma phenotype and with\n nasal polyps. Dupilumab may be the therapy of choice of monoclonal antibodies in cases of moderate-severe atopic dermatitis accompanied by OCS-dependent severe asthma. For reslizumab and omalizumab, placebo controlled double-blind studies conducted with OCS-dependent patient populations are\n needed.  <jats:bold>Conclusion:<\/jats:bold> Biologics are effective in the \u201cOCS-dependent asthma\u201d phenotype as add-on therapy. It seems that chronic OCS use in OCS-dependent asthma will be replaced by biologic agents that specifically target type 2 inflammation, along with a much better\n safety profile. However, real-life studies that compare these biologics in OCS-dependent severe asthma are urgently needed.<\/jats:p>","DOI":"10.2500\/aap.2020.41.200015","type":"journal-article","created":{"date-parts":[[2020,5,7]],"date-time":"2020-05-07T04:38:52Z","timestamp":1588826332000},"page":"151-157","source":"Crossref","is-referenced-by-count":6,"title":["Biologics for oral corticosteroid-dependent asthma"],"prefix":"10.2500","volume":"41","author":[{"given":"\u0130nsu","family":"Y\u0131lmaz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1355","container-title":["Allergy and Asthma Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ingentaconnect.com\/content\/ocean\/aap\/2020\/00000041\/00000003\/art00004","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,27]],"date-time":"2020-05-27T04:42:33Z","timestamp":1590554553000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ingentaconnect.com\/content\/10.2500\/aap.2020.41.200015"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,1]]},"references-count":0,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,5,1]]}},"alternative-id":["1088-5412(20200501)41:3L.151;1-"],"URL":"https:\/\/doi.org\/10.2500\/aap.2020.41.200015","relation":{},"ISSN":["1088-5412"],"issn-type":[{"value":"1088-5412","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5,1]]}}}